Therapies that target the prostacyclin pathway hold promise as chronic CTEPH treatment, a meta-analysis of controlled trials ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

Normally, these nasty effects are kept in check by another chemical called prostacyclin. But prostacyclin is made, in part, with the help of Cox-2 enzymes -- the enzymes that drugs like Celebrex ...

Objectives The use of aspirin to prevent cardiovascular disease in vasospastic angina (VSA) patients without significant stenosis has yet to be investigated. This study aimed to investigate the ...

Learn more at https://SERB.com. AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in ...

Patients with recorded episodes of SDV-related complications (digital ulceration, critical digital ischaemia or digital gangrene), requiring surgical amputation, digital sympathectomy or admissions ...

ACS: Acute coronary syndrome; CV: Cardiovascular; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; TIA: Transient ischemic attack.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has ...

United Therapeutics is also in search of an effective medicine with trepostinil, a prostacyclin mimetic, currently in phase 3 development for IPF. As is Bristol-Myers Squibb, recently announcing ...

The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within ...